How government-dependent was REGENERON PHARMACEUTICALS, INC. in fiscal year 2024?

In fiscal year 2024, US federal contract obligations equal at least -0.0% of REGENERON PHARMACEUTICALS, INC.'s reported revenue - $-1.4M in federal awards against $14.2B in revenue as filed with the SEC.

Cite as: FACTANKER, https://factanker.com/entity/2dc9492b-8afa-424a-a63e-3c4cc18bafa8/government-dependency/2024

Fiscal year	Revenue (SEC, as filed)	Federal obligations	Share	Data status
FY 2025	$14.3B	$-331.7M	≥ -2.3%	contracts only
FY 2024	$14.2B	$-1.4M	≥ -0.0%	contracts only

Evidence
Revenue FY 2024: evidence fact bc1010ea… (SEC filing)
Federal obligations FY 2024: sum of 5 award records (USAspending bulk data)
Identity consolidation: CIK 0000872589 · LEI 549300RCBFWIRX3HYQ56 · UEI N3F9MH7E6HD6 - linked via evidence-backed same_as facts, see all facts of this organization

Methodology & sources
Revenue: company fiscal year, as filed with the SEC (XBRL concept per evidence fact). Obligations: US federal fiscal year of the award date, consolidated across all registrations of the corporate group. Computed in the database, precomputed weekly - never by a model. Sources: SEC EDGAR, USAspending (public domain).

Not claimed

The two periods do not align exactly: revenue follows the company's fiscal year, obligations the US federal fiscal year (Oct-Sep).
Years marked 'contracts only': grant/assistance awards are not yet loaded - the share is a floor, not the full figure.
Fiscal years without a share: obligations base files not yet loaded; a missing value means missing load, not zero government business.
Obligations are amounts obligated, not amounts paid out.
The share consolidates all registrations of the corporate group via evidence-backed identity links (same_as facts).

Latest fiscal year & all years · REGENERON PHARMACEUTICALS, INC. - all facts · Use this metric in your own models: JSON/API · API/MCP quickstart